The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

被引：18

作者：

Mize, Dara L. Eckerle ^{[1
]}

Salehi, Marzieh ^{[2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Div Diabet Endocrinol & Metab, Nashville, TN 37232 USA

[2] Univ Cincinnati, Dept Internal Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA

来源：

CURRENT DIABETES REPORTS | 2013年 / 13卷 / 03期

关键词：

GLP-1; DPP-4; GLP-1 receptor agonists; inhibitors; Incretin; Type; 2; diabetes; Weight loss; Hypoglycemia; Cardiovascular risk factors; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; OPEN-LABEL TRIAL; DEPENDENT INSULINOTROPIC POLYPEPTIDE; EXENATIDE SYNTHETIC EXENDIN-4; INITIAL COMBINATION THERAPY; IMPROVES GLYCEMIC CONTROL; NON-INFERIORITY TRIAL; TWICE-DAILY EXENATIDE;

D O I：

10.1007/s11892-013-0377-9

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.

引用

页码：307 / 318

页数：12

共 124 条

[1]

Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells [J].

Abraham, EJ ;

Leech, CA ;

Lin, JC ;

Zulewski, H ;

Habener, JF .

ENDOCRINOLOGY, 2002, 143 (08) :3152-3161

[2]

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review [J].

Aroda, Vanita R. ;

Henry, Robert R. ;

Han, Jenny ;

Huang, Wenying ;

DeYoung, Mary Beth ;

Darsow, Tamara ;

Hoogwerf, Byron J. .

CLINICAL THERAPEUTICS, 2012, 34 (06) :1247-1258

[3]

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes [J].

Aschner, P. ;

Katzeff, H. L. ;

Guo, H. ;

Sunga, S. ;

Williams-Herman, D. ;

Kaufman, K. D. ;

Goldstein, B. J. .

DIABETES OBESITY & METABOLISM, 2010, 12 (03) :252-261

[4]

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J].

Aschner, Pablo ;

Kipnes, Mark S. ;

Lunceford, Jared K. ;

Sanchez, Matilde ;

Mickel, Carolyn ;

Williams-Herman, Debora E. .

DIABETES CARE, 2006, 29 (12) :2632-2637

[5]

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial [J].

Aschner, Pablo ;

Chan, Juliana ;

Owens, David R. ;

Picard, Sylvie ;

Wang, Edward ;

Dain, Marie-Paule ;

Pilorget, Valerie ;

Echtay, Akram ;

Fonseca, Vivian .

LANCET, 2012, 379 (9833) :2262-2269

[6]

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[7]

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences [J].

Baetta, Roberta ;

Corsini, Alberto .

DRUGS, 2011, 71 (11) :1441-1467

[8]

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin [J].

Barnett, Anthony H. ;

Charbonnel, Bernard ;

Donovan, Mark ;

Fleming, Douglas ;

Chen, Roland .

CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) :513-523

[9]

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial [J].

Bergenstal, Richard M. ;

Wysham, Carol ;

MacConell, Leigh ;

Malloy, Jaret ;

Walsh, Brandon ;

Yan, Ping ;

Wilhelm, Ken ;

Malone, Jim ;

Porter, Lisa E. .

LANCET, 2010, 376 (9739) :431-439

[10]

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers [J].

Bergman, AJ ;

Stevens, C ;

Zhou, YY ;

Yi, BM ;

Laethem, M ;

De Smet, M ;

Snyder, K ;

Hilliard, D ;

Tanaka, W ;

Zeng, W ;

Tanen, M ;

Wang, AQ ;

Chen, L ;

Winchell, G ;

Davies, MJ ;

Ramael, S ;

Wagner, JA ;

Herman, GA .

CLINICAL THERAPEUTICS, 2006, 28 (01) :55-72

← 1 2 3 4 5 6 7 8 9 10 →